Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
Stocks fell sharply on Thursday as investors started to fear the U.S.-China trade war is slowing the economy.Marketsread more
The charges allege he published secret documents obtained by former Army intelligence analyst Chelsea Manning, some of which included the disclosure of foreigners who were...Politicsread more
See which stocks are posting big moves after the bell on Thursday, May 23.Market Insiderread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
Sentiment is "not negative enough to trigger a huge rally ... unless we get some kind of real breakthrough with China," Jim Cramer says.Mad Money with Jim Cramerread more
Oracle co-founder Larry Ellison disclosed a $1 billion stake in Tesla in late December. It's now worth about $580 million.Technologyread more
Investors rushed into the safety of bonds Thursday and sold stocks, as it appeared the trade war could be prolonged and more painful for the world economy than expected.Market Insiderread more
The e-mail's optimistic tone helped Tesla shares turn positive for the first time in seven days.Technologyread more
The president signaled that he is open to negotiating U.S. restrictions on the Chinese telecom giant as part of a broader trade deal, even as he called Huawei a "very...Politicsread more
"We still haven't seen the big estimate cuts that we can expect from the analysts who weren't expecting President Trump to keep raising tariffs," Jim Cramer says.Mad Money with Jim Cramerread more
YOKNEAM, Israel, July 30, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for aesthetic, surgical and ophthalmology applications, today announced that the LightSheer DESIRE received a Professional Notable honor in the Commerical Equipment category of the 2015 Core77 Design Awards program.
A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=34802
A video accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=34803
LightSheer DESIRE is one of the latest innovations in Lumenis' flagship laser hair removal product line. It combines the elite technology that made LightSheer the gold standard in laser hair removal with an innovative design that provides a revolutionary solution for both the therapist and the patient.
The portable, upgradeable console is ideal for dermatology and aesthetic practices seeking to enter the rapidly growing laser hair removal market.
The design approach of LightSheer DESIRE focused primarily on the user interface. In collaboration with Taga, an industrial product design and development agency, Lumenis created the experience through a large fully customized 15 " touch screen which includes an advanced graphical user interface with intuitive presets for fast learning curve and easy treatment delegation, and forms a user-friendly experience for the therapist and a calming atmosphere for the patient.
"At Lumenis we believe that a superior product is measured not only by its advanced technology and performance, but also by its appearance and design," said Tzipi Ozer-Armon, CEO of Lumenis. "In search for a ground-breaking solution within our commitment to continued innovation, we concentrated on the user experience by creating an innovative design, and are thrilled that a distinguished international design directory as the Core77 recognized our product for excellence."
LightSheer DESIRE provides both faster treatment time and enhanced patient comfort. With High-Speed Integrated Technology (HIT™), procedure time is reduced by more than 75% and large areas such as the back and legs can be treated rapidly using the 22x35mm spot size. Lumenis' patented ChillTip™ Technology improves patient comfort by cooling the skin prior to and throughout the treatment.
About the Core77 Design Awards
Recognizing excellence in all areas of design enterprise, the Core77 Design Awards celebrates the richness of the design profession and its practitioners. They present 14 categories of entry, providing designers, researchers and makers a unique opportunity to communicate the intent, rigor and passion behind their efforts. From client work to self-initiated projects and entrepreneurial endeavors, they embrace a wide diversity of enterprise: commercial, cultural, social, environmental and discursive.
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: For further information: Mai Duong Lazar Partners Ltd. (646) 871-8492